RE:Financials let's hope as this is a bit a black box.
On May 27th they announced the successful tender in the UK for the exclusive distribution rights for two strengths of pemetrexed (100mg and 500mg) by the National Health Service of England ("NHS England") for the Central and South West Region of England. The awarded NHS England tender is the Company's first awarded tender for pemetrexed in the United Kingdom ("UK"). The awarded tender has the following projected annual supply quantities based on the award debrief provided by NHS England: pemetrexed 100mg – 10,500 vials pemetrexed 500mg – 9,300 vials The tender will commence on June 15, 2021 and has a duration of 12.5 months. WPEL continues to apply for additional tenders in the UK and across the European Union ("EU") for pemetrexed and hopes to further increase its presence across Europe. "Waverley Pharma is pleased to announce our first awarded pemetrexed tender in the UK, adding to the continued growth of our oncology presence in this market" stated Larry Thiessen, President and Chief Executive Officer.
No further news if they made any other achievements